AI race in a billion-dollar market: How are Evotec, NetraMark Holdings, and Novo Nordisk doing in the race?

Evotec – Ahead of the first quarter figures

Hamburg-based biotechnology company Evotec looks back on an ambivalent year in 2024. Group revenue rose moderately by 2% to EUR 797 million, driven by partnerships with pharmaceutical players such as Bayer and Novo Nordisk. However, adjusted EBITDA fell to EUR 22.6 million, weighed down by reorganization costs of EUR 54.9 million. Operating income slipped into the red at EUR -142.5 million, and the share price lost over 60% of its value. For 2025, the Company expects revenues to stagnate and EBITDA to decline further to between EUR 5 and 15 million. The planned efficiency measures are not likely to take full effect until 2026. The figures for the first quarter will be presented on May 6.

One ray of hope is the strategic alliance with Bristol Myers Squibb (BMS) in the field of protein degradation. The collaboration, which has been ongoing since 2018, combines Evotec's AI-powered platforms with BMS' Cereblon library to develop "Molecular Glue Degraders" – active compounds that specifically degrade disease-relevant proteins. Recent successes triggered payments of USD 75 million to Evotec and strengthened the pipeline in oncology. "We are well on track to achieve our goals," emphasizes CSO Cord Dohrmann. The technology addresses previously difficult-to-treat target proteins and could have blockbuster potential in the long term.

Deutsche Bank sees Evotec's latest strategy adjustment as a step in the right direction. The price target has been set at EUR 7, and the rating has been raised from "Sell" to "Hold." Analysts point to the Company's plausible 2025 targets but also emphasize the risks of the transition year 2024. Cost reductions and the rapid implementation of the pipeline, therefore, remain decisive factors. The BMS cooperation, which is seen as a bridge between short-term stabilization and long-term growth momentum, could become a key factor. Market observers have responded positively to this development, with the share currently trading at EUR 7.38.

NetraMark – AI-driven optimization of clinical trials

NetraMark is positioning itself in the pharmaceutical sector with a specialized AI approach. The Company focuses on optimizing late-stage clinical trials (Phase 2/3), which traditionally have high dropout rates. The core product is the in-house software NetraAI, which is capable of identifying hidden correlations and subpopulations from patient data. This technology enables the design of more targeted studies, shortens recruitment periods, and increases the statistical probability of success. A decisive advantage is that, unlike many competing solutions, the platform can also work with limited data sets.

NetraMark recently achieved a milestone through its cooperation with Worldwide Clinical Trials (WCT), a leading contract research organization. WCT is integrating the NetraAI platform into its services for pharmaceutical companies – initially in Phase 2 studies in neurology and oncology and selected Phase 3 trials. The collaboration aims to increase the chances of success through AI-supported patient stratification and data correlation while reducing the duration of studies. The partnership gives NetraMark access to WCT's global network of over 3,500 employees in 60 countries. In the long term, this could make the technology the new standard in patient-centered study optimization.

NetraMark benefits from growing pressure on pharmaceutical companies to make development processes more cost-efficient. Studies show that over 65% of Phase 3 trials fail – this is where the AI solution comes in to minimize risks and costs. A recent example is its successful application in clinical depression, where NetraAI increased model accuracy by 28%. With the recently launched NetraAI 2.0 platform and additional partnerships, such as with the National Institute of Health, the Company is positioning itself as a key player in a dynamically growing market. Since October 2024, the share price has risen by over 700% at its peak. The current price is CAD 1.51.

Interview by Lyndsay Malchuk with George Achilleos, CEO of NetraMark

Novo Nordisk – Between innovative strength and market dynamics

Novo Nordisk is holding its own in a highly competitive obesity market despite the dominance of Eli Lilly's tirzepatide. Although early study data for the promising CagriSema were disappointing, the Company is responding with adjusted dosages and a new Phase 3 study. At the same time, Novo is working on optimizing semaglutide. Higher doses have shown improved weight loss in tests. External collaborations, such as with Ascendis Pharma on monthly injection technology and United Biotechnology on a triple agonist, underscore the strategy of diversifying the pipeline through partnerships.

The focus is on expanding distribution channels. Partnerships with telemedicine platforms such as Hims & Hers and LifeMD enable direct access to Wegovy for patients. These collaborations capitalize on the growing demand for digital health solutions and strengthen Novo Nordisk's presence in the lifestyle segment. At the same time, the Company is positioning itself as a flexible provider - in addition to Wegovy, competing products such as Eli Lilly's tirzepatide are also being integrated into these platforms to appeal to broader target groups.

A US court ruling against generic versions of Ozempic and Wegovy strengthens Novo Nordisk's market position. The FDA ended its shortage declaration for GLP-1 drugs, which is forcing competing manufacturers out of the market. This development favors established players, as original drugs can now be sold without price-depressing generics. In the long term, this could stabilize margins and enable Novo Nordisk to invest resources in developing new therapeutic approaches, such as oral GLP-1 variants, in order to withstand competition. The share price appears to have found a floor in the EUR 53 range and has started to rebound. One share currently costs EUR 58.33.

The pharmaceutical industry is struggling to strike a balance between innovation and profitability. Despite shrinking margins, Evotec is fighting for long-term pipeline relevance with its AI-driven protein degradation alliance with Bristol Myers Squibb. NetraMark is revolutionizing clinical trials with AI-based patient optimization – its partnership with Worldwide Clinical Trials and a stock rally highlight its disruptive potential. Novo Nordisk is holding its own in the fight against obesity through flexible distribution partnerships, legal victories against generics, and adjusted dosing strategies for semaglutide. While AI sets the pace, the ability to translate technology into profitable therapies will determine who dominates the era of data-driven medicine.